Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044412410> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2044412410 endingPage "A226" @default.
- W2044412410 startingPage "A226" @default.
- W2044412410 abstract "Prolongation of survival or prevention of bone metastases are the main objectives of phase 3 studies in MPC patients refractory to hormone therapy or castration resistant (HRPC/CRPC). In addition to efficacy, PROs and tolerability should be assessed to define treatment benefit, as PROs (eg. quality of life [QOL] and pain response) measure the patient's subjective experience and can be correlated with hard outcomes (eg, pain intensity and survival). A systematic review evaluated the number of studies reporting PROs in HRPC/CRPC; tolerability was a secondary objective. A predefined search strategy was used (2007-2011) in Medline, EMBASE, Cochrane Library, conference proceedings (ASCO/ESMO), AHRQ, NICE, and NHS HEED. Controlled clinical trials, retrospective cohort studies, and literature reviews were included. Studies in children, non-English language studies, case reports/series, and studies with preliminary/incomplete results were excluded. Of 79 studies identified, only 14 (18%) evaluated PROs and tolerability. The most common PRO was pain, measured using the Present Pain Intensity (PPI) instrument. Abiraterone showed statistically significant improvements in survival and pain response. Cabazitaxel did not show improvement in pain response, despite survival benefit. Bone-targeted agents (zoledronic acid/denosumab) prolonged the time to first on-study skeletal related event (SRE) but did not assess PROs. Radium-223, a new bone-targeted radiopharmaceutical agent emitting α-particles, included QOL as a secondary endpoint and showed survival benefit. Toxicities of the new therapies also require careful consideration. Fluid retention, hypertension, and hypokalemia are characteristic toxicities with abiraterone (predominately Grade 1/2). Cabazitaxel has a high incidence of Grade 3/4 neutropenia (82%), febrile neutropenia (8%), and diarrhea (6%). Radium-223 is well tolerated with a low incidence of Grade 3/4 neutropenia (2%). PROs are incorporated in studies of new therapies for MPC, although mainly as secondary endpoints with delayed reporting of results. Therefore, safety profiles play an important role in individualized treatment selections." @default.
- W2044412410 created "2016-06-24" @default.
- W2044412410 creator A5000203747 @default.
- W2044412410 creator A5039394051 @default.
- W2044412410 creator A5059381074 @default.
- W2044412410 creator A5081666026 @default.
- W2044412410 date "2012-06-01" @default.
- W2044412410 modified "2023-09-27" @default.
- W2044412410 title "PCN105 Patient-Reported Outcomes (PROs) and Tolerability of Therapeutic Agents in Patients With Metastatic Prostate Cancer (MPC): A Systematic Literature Review" @default.
- W2044412410 doi "https://doi.org/10.1016/j.jval.2012.03.1222" @default.
- W2044412410 hasPublicationYear "2012" @default.
- W2044412410 type Work @default.
- W2044412410 sameAs 2044412410 @default.
- W2044412410 citedByCount "0" @default.
- W2044412410 crossrefType "journal-article" @default.
- W2044412410 hasAuthorship W2044412410A5000203747 @default.
- W2044412410 hasAuthorship W2044412410A5039394051 @default.
- W2044412410 hasAuthorship W2044412410A5059381074 @default.
- W2044412410 hasAuthorship W2044412410A5081666026 @default.
- W2044412410 hasBestOaLocation W20444124101 @default.
- W2044412410 hasConcept C121608353 @default.
- W2044412410 hasConcept C126322002 @default.
- W2044412410 hasConcept C143998085 @default.
- W2044412410 hasConcept C197934379 @default.
- W2044412410 hasConcept C2776139714 @default.
- W2044412410 hasConcept C2776286101 @default.
- W2044412410 hasConcept C2776326535 @default.
- W2044412410 hasConcept C2776541429 @default.
- W2044412410 hasConcept C2777899217 @default.
- W2044412410 hasConcept C2778375690 @default.
- W2044412410 hasConcept C2778971682 @default.
- W2044412410 hasConcept C2780192828 @default.
- W2044412410 hasConcept C71924100 @default.
- W2044412410 hasConceptScore W2044412410C121608353 @default.
- W2044412410 hasConceptScore W2044412410C126322002 @default.
- W2044412410 hasConceptScore W2044412410C143998085 @default.
- W2044412410 hasConceptScore W2044412410C197934379 @default.
- W2044412410 hasConceptScore W2044412410C2776139714 @default.
- W2044412410 hasConceptScore W2044412410C2776286101 @default.
- W2044412410 hasConceptScore W2044412410C2776326535 @default.
- W2044412410 hasConceptScore W2044412410C2776541429 @default.
- W2044412410 hasConceptScore W2044412410C2777899217 @default.
- W2044412410 hasConceptScore W2044412410C2778375690 @default.
- W2044412410 hasConceptScore W2044412410C2778971682 @default.
- W2044412410 hasConceptScore W2044412410C2780192828 @default.
- W2044412410 hasConceptScore W2044412410C71924100 @default.
- W2044412410 hasIssue "4" @default.
- W2044412410 hasLocation W20444124101 @default.
- W2044412410 hasOpenAccess W2044412410 @default.
- W2044412410 hasPrimaryLocation W20444124101 @default.
- W2044412410 hasRelatedWork W2000159285 @default.
- W2044412410 hasRelatedWork W2028719241 @default.
- W2044412410 hasRelatedWork W2059294441 @default.
- W2044412410 hasRelatedWork W2069580608 @default.
- W2044412410 hasRelatedWork W2132069496 @default.
- W2044412410 hasRelatedWork W2414185687 @default.
- W2044412410 hasRelatedWork W2568045406 @default.
- W2044412410 hasRelatedWork W3169177117 @default.
- W2044412410 hasRelatedWork W4286296027 @default.
- W2044412410 hasRelatedWork W2181783601 @default.
- W2044412410 hasVolume "15" @default.
- W2044412410 isParatext "false" @default.
- W2044412410 isRetracted "false" @default.
- W2044412410 magId "2044412410" @default.
- W2044412410 workType "article" @default.